Published in Nat Med on March 23, 2014
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A (2014) 2.23
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathog (2015) 2.19
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog (2014) 2.10
HIV-1 DNA predicts disease progression and post-treatment virological control. Elife (2014) 2.07
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell (2014) 1.91
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest (2015) 1.76
Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol (2015) 1.73
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission. PLoS Pathog (2015) 1.71
Immunologic strategies for HIV-1 remission and eradication. Science (2014) 1.70
The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS (2015) 1.68
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine (2015) 1.42
Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat Med (2016) 1.41
Are T cells the only HIV-1 reservoir? Retrovirology (2016) 1.39
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS (2016) 1.25
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog (2015) 1.18
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest (2015) 1.13
Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. Open Forum Infect Dis (2015) 1.08
Understanding HIV latency: the road to an HIV cure. Annu Rev Med (2015) 1.07
Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother (2015) 1.05
Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. PLoS Pathog (2014) 1.04
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog (2015) 1.02
Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One (2014) 0.99
Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology (2014) 0.99
Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Mol Ther (2015) 0.98
Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Sci Rep (2016) 0.98
Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics (2015) 0.98
Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc Natl Acad Sci U S A (2014) 0.97
Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res Hum Retroviruses (2015) 0.94
Finding a cure for human immunodeficiency virus-1 infection. Infect Dis Clin North Am (2014) 0.93
Latency reversal and viral clearance to cure HIV-1. Science (2016) 0.92
Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses (2015) 0.92
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathog (2016) 0.90
A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads. J Infect Dis (2015) 0.88
Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs. Org Lett (2014) 0.88
Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems. PLoS One (2016) 0.87
H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells. J Virol (2015) 0.87
A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy. J Virol (2015) 0.87
Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA. J Clin Microbiol (2016) 0.86
Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells. PLoS Pathog (2015) 0.86
Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold. Org Lett (2014) 0.86
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells. PLoS Pathog (2015) 0.86
HIV-specific CD8+ T cells and HIV eradication. J Clin Invest (2016) 0.85
Short chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications. Virology (2014) 0.85
Synthesis of seco-B-ring bryostatin analogue WN-1 via C-C bond-forming hydrogenation: critical contribution of the B-ring in determining bryostatin-like and phorbol 12-myristate 13-acetate-like properties. J Am Chem Soc (2014) 0.85
Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core. J Am Chem Soc (2014) 0.85
Molecular mechanisms of HIV latency. J Clin Invest (2016) 0.85
Recent developments in the effort to cure HIV infection: going beyond N = 1. J Clin Invest (2016) 0.85
HIV-1 functional cure: will the dream come true? BMC Med (2015) 0.84
Measuring the latent reservoir in vivo. J Clin Invest (2016) 0.84
BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe (2015) 0.83
Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. Clin Infect Dis (2015) 0.83
The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin Biol Ther (2015) 0.83
Apoptosis-induced activation of HIV-1 in latently infected cell lines. Retrovirology (2015) 0.83
HIV eradication symposium: will the brain be left behind? J Neurovirol (2015) 0.82
Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells. J Virol (2015) 0.81
Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapy. Cell Mol Bioeng (2014) 0.81
Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS (2015) 0.81
Modeling the timing of antilatency drug administration during HIV treatment. J Virol (2014) 0.81
HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells. Retrovirology (2016) 0.81
Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. AIDS (2017) 0.80
Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1. Sci Rep (2015) 0.80
Minor Contribution of Chimeric Host-HIV Readthrough Transcripts to the Level of HIV Cell-Associated gag RNA. J Virol (2015) 0.80
Translational challenges in targeting latent HIV infection and the CNS reservoir problem. J Neurovirol (2014) 0.80
Ultrasensitive HIV-1 p24 detects single infected cells and differences in reservoir induction by latency-reversal agents. J Virol (2017) 0.80
A Minor Subset of Super Elongation Complexes Plays a Predominant Role in Reversing HIV-1 Latency. Mol Cell Biol (2016) 0.80
Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells. Virology (2015) 0.80
Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy. PLoS One (2014) 0.80
Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+ T Cells In Vitro. J Virol (2016) 0.80
Conformation-activity relationships of polyketide natural products. Nat Prod Rep (2015) 0.80
Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol Med (2015) 0.80
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis (2016) 0.80
Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch. Retrovirology (2015) 0.79
Function through synthesis-informed design. Acc Chem Res (2015) 0.79
Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther (2014) 0.79
Position effects influence HIV latency reversal. Nat Struct Mol Biol (2016) 0.79
Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus. World J Virol (2015) 0.79
Reactivation of latent HIV-1 provirus via targeting protein phosphatase-1. Retrovirology (2015) 0.79
The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication. EBioMedicine (2016) 0.79
Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. PLoS Pathog (2016) 0.78
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. Antimicrob Agents Chemother (2015) 0.78
Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors. Mol Ther (2016) 0.78
The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. Sci Rep (2016) 0.78
Enigma of HIV-1 latent infection in astrocytes: an in-vitro study using protein kinase C agonist as a latency reversing agent. Microbes Infect (2015) 0.78
Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy. J Am Chem Soc (2015) 0.78
A passive-flow microfluidic device for imaging latent HIV activation dynamics in single T cells. Integr Biol (Camb) (2015) 0.78
Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation. Nat Commun (2016) 0.78
IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI Insight (2017) 0.77
Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals. Proc Natl Acad Sci U S A (2014) 0.77
HIV eradication: combinatorial approaches to activate latent viruses. Viruses (2014) 0.77
Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Front Immunol (2015) 0.77
Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb. AIDS Res Hum Retroviruses (2016) 0.77
Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. PLoS Pathog (2016) 0.77
In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. J Virol (2015) 0.77
Standard vaccines increase HIV-1 transcription during antiretroviral therapy. AIDS (2016) 0.77
Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor. AIDS Res Hum Retroviruses (2016) 0.76
Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection. J Virus Erad (2015) 0.76
Multifarious immunotherapeutic approaches to cure HIV-1 infection. Hum Vaccin Immunother (2015) 0.76
Manipulation of the host protein acetylation network by human immunodeficiency virus type 1. Crit Rev Biochem Mol Biol (2015) 0.76
Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells. PLoS Pathog (2017) 0.76
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 2.47
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog (2013) 2.02
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem (2012) 1.85
Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep (2012) 1.84
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res (2012) 1.73
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis (2012) 1.72
The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS (2011) 1.67
Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J Virol (1990) 1.46
A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis (2013) 1.46
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
A novel PCR assay for quantification of HIV-1 RNA. J Virol (2013) 1.25
Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS (2013) 1.24
HIV latency: experimental systems and molecular models. FEMS Microbiol Rev (2012) 1.19
Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem (2013) 1.17
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12
Induction of HIV-1 replication by allogeneic stimulation. J Immunol (1999) 0.99
Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res Hum Retroviruses (2000) 0.97
Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med (2016) 1.48
A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nat Protoc (2014) 0.86
One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. KI Rep (2021) 0.75